Cyberonics Stays Neutral - Analyst Blog
July 07 2011 - 11:20AM
Zacks
We recently reiterated our Neutral recommendation on
Cyberonics (CYBX) with a target price of $30.00,
following our assessment of its fourth quarter 2011 results.
Cyberonics reported fourth quarter 2011 EPS of 26 cents, which
missed the Zacks Consensus Estimate of 29 cents and were well below
the year-ago quarter adjusted EPS of 40 cents. The year-over-year
decline was attributable to significant increase in income tax
expense ($5.5 million in the reported quarter compared with the
year-ago quarter level of $.03 million).
Cyberonics develops and markets Vagus Nerve Stimulation (VNS)
Therapy System, which is approved by the US Food and Drug
Administration (FDA) for the treatment of refractory epilepsy and
treatment-resistant depression (TRD).
During the quarter, Cyberonics witnessed a continuous expansion
in its top line, attributable to the company’s pioneer product, VNS
Therapy System, especially for the treatment of epilepsy. Revenues
increased 7.1% year over year to $51.1 million in the reported
quarter but were marginally below the Zacks Consensus Estimate of
$52 million.
In fiscal 2011,Epilepsy unit sales increased 6% in the US on the
back of both influx of patients and replacements. This was strongly
driven by higher volume and increased average selling prices. The
company’s US epilepsy revenue surged significantly from $82 million
in fiscal 2007 to $160 million in 2011. This reflects a 97% upside
in revenues within a span of four years.
Cyberonics also provided its financial outlook for fiscal 2012.
The company expects revenues and income from operations in the
range of $212 – $215 million and $54 – $57 million,
respectively.
The company is currently emphasizing on its international
business by expanding its epilepsy portfolio through direct sales
force and distributors in Europe, Latin America, Russia and Asia
(including Japan, China and India) However, the company expects
international growth to resume in fiscal 2012.
Moreover, the company is focusing on research and development in
the field of VNS Therapy for patients with refractory epilepsy
specifically, seizure detection, responsive stimulation and
associated technology.
However, stiff competition from Medtronic (MDT)
and St. Jude Medical Inc. (STJ) in the
neuromodulation space as well as the mounting third-party
reimbursement issues may adversely affect the company’s performance
going forward.
CYBERONICS INC (CYBX): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
Zacks Investment Research
SJM (NYSE:STJ)
Historical Stock Chart
From Jun 2024 to Jul 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Jul 2023 to Jul 2024